WaferGen Biosystems is an innovative genomic analysis company founded in 2002 and headquartered in the United States. The company's flagship product is the advanced SmartChip Real-Time PCR System, which is designed for profiling and validation of gene expression patterns (biomarkers) on a single platform. This system offers high-throughput capabilities, including microRNA and mRNA gene expression profiling, and SNP genotyping. WaferGen Biosystems operates in the biotechnology, life sciences, and pharmaceutical industries.
The latest investment in WaferGen Biosystems amounted to $15.00M, in the form of a Post-IPO Equity investment on 27 August 2013.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $15.00M | - | 27 Aug 2013 | |
| Post-IPO Equity | $30.55M | - | 01 Jun 2012 | |
| Post-IPO Equity | $30.00M | 3 |
|
31 May 2011 |
| Post-IPO Equity | $5.09M | - | 24 Feb 2010 | |
| Post-IPO Equity | $6.26M | - | 15 Sep 2009 |
No recent news or press coverage available for WaferGen Biosystems.
We care about your data, and we'd love to use cookies make your experience better.
